This study [4827-005 (post market)] is designed to evaluate the safety and efficacy of
long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris,
psoriatic arthritis) who have completed Study 4827-003 (Study 003) and in subjects with
pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study
4827-004 (Study 004). 4827-005 study was conducted as phase 3 clinical trial until July 4th
2016 (approval date in Japan). After that date 4827-005 study was switched to phase 4 study.